Results 61 to 70 of about 70,790 (271)

The risk of tuberculosis infection in Saudi patients receiving adalimumab, etanercept, and tocilizumab therapy

Journal of Infection and Public Health
Background: The risk of infection including tuberculosis (TB) infection or reactivation during biological therapy with the current various clinical application is a major concern. This risk may be higher in countries endemic to TB.
Abdulaziz Boqaeid, Laila Layqah, Amgad Alonazy, Mutaz Althobaiti, Al-zahraa Almahlawi, Abdullah Al-Roqy, Omar Baharoon, Abdullah Alsaeedi, Jinan Shamou, Salim Baharoon   +9 more
doaj   +1 more source

Etanercept-Synthesising Mesenchymal Stem Cells Efficiently Ameliorate Collagen-Induced Arthritis

Scientific Reports, 2017
Mesenchymal stem cells (MSCs) have multiple properties including anti-inflammatory and immunomodulatory effects in various disease models and clinical treatments. These beneficial effects, however, are sometimes inconsistent and unpredictable.
Narae Park, Yeri Alice Rim, Hyerin Jung, Juryun Kim, Hyoju Yi, Youngkyun Kim, Y. Jang, S. Jung, J. Lee, S. Kwok, Sung-Hwan Park, J. Ju   +11 more
semanticscholar   +1 more source

Measuring the Impact of the Substitution of Innovator Biologics With Biosimilars on Uptake and Costs Among Ontario Public Drug Benefit Recipients

Clinical Pharmacology &Therapeutics, EarlyView.
In Ontario, biologics have historically represented a small proportion of public drug claims but a large proportion of spending. Biosimilars, lower cost alternatives to biologics, offer a potential solution to the rising spending on biologics. From March 2023 to January 2024, the Ontario Ministry of Health required public drug program beneficiaries on ...
Anita Iacono, Martin K. H. Ho, Joanna Yang, Tonya Campbell, William Wynne, Dana Shearer, Lene Andersen, Eric Majer, Shaleesa Ledlie, Mina Tadrous, Tara Gomes   +10 more
wiley   +1 more source

AB1615 EVALUATION OF THE NOCEBO EFFECT WHEN SWITCHING FROM THE ORIGINATOR MOLECULE TO A BIOSIMILAR IN A NORMANDY RETROSPECTIVE COHORT OF PATIENTS WITH INFLAMMATORY RHEUMATISM TREATED WITH ETANERCEPT OR ADALIMUMAB (BIONORIC STUDY) [PDF]

, 2023
O. Hagege, Thierry Lequerré, Christian Marcelli, R. Varin, D. Alcaix, Anne‐Joëlle Weber, Sorina‐Dana Mihailescu, E. Duhamel, O. Vittecoq   +8 more
openalex   +1 more source

Modification of structural lesions on MRI of the sacroiliac joints by etanercept in the EMBARK trial: a 12-week randomised placebo-controlled trial in patients with non-radiographic axial spondyloarthritis

Annals of the Rheumatic Diseases, 2017
Objective To evaluate the impact on structural lesions observed on MRI in the sacroiliac joints (SIJ) at 12 weeks in patients with non-radiographic axial spondyloarthritis (nr-axSpA) receiving etanercept or placebo in EMBARK (Effect of Etanercept on ...
W. Maksymowych, S. Wichuk, M. Dougados, H. Jones, R. Pedersen, A. Szumski, L. Marshall, J. Bukowski, R. Lambert   +8 more
semanticscholar   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source

Tumor Necrosis Factor-Alpha Targeting Can Protect against Arthritis with Low Sensitization to Infection

Frontiers in Immunology, 2017
Tumor necrosis factor-alpha (TNF-α) blockade is an effective treatment for rheumatoid arthritis (RA) and other inflammatory diseases, but in patients, it is associated with reduced resistance to the infectious agents Mycobacterium tuberculosis and ...
Nadia Belmellat, Nadia Belmellat, Luca Semerano, Luca Semerano, Luca Semerano, Noria Segueni, Diane Damotte, Patrice Decker, Patrice Decker, Bernhard Ryffel, Bernhard Ryffel, Valérie Quesniaux, Marie-Christophe Boissier, Marie-Christophe Boissier, Marie-Christophe Boissier, Eric Assier, Eric Assier   +16 more
doaj   +1 more source

Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis

Current Rheumatology Reports, 2018
Purpose of ReviewEtanercept was the first tumour necrosis factor inhibitor approved to treat rheumatoid arthritis (RA) in the United States (US) and Europe.
L. Chadwick, S. Zhao, E. Mysler, R. Moots   +3 more
semanticscholar   +1 more source

Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)

American Journal of Clinical Dermatology, 2017
BackgroundPatients with psoriasis who have an inadequate response to one biologic may benefit from switching to a new biologic, such as ixekizumab, a high affinity monoclonal antibody that selectively targets interleukin (IL)-17A.ObjectiveOur aim was to ...
A. Blauvelt, K. Papp, C. Griffiths, L. Puig, J. Weisman, Y. Dutronc, L. Kerr, D. Ilo, L. Mallbris, M. Augustin   +9 more
semanticscholar   +1 more source